Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel trevatide
- Development stage
- Phase 3
- Lead developer
- Angiochem
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Recombinant Proteins and Enzymes, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel trevatide is a peptide-drug conjugate, composed of three molecules of the chemotherapeutic agent paclitaxel covalently linked by a cleavable ester to the proprietary 19-amino-acid peptide Angiopep-2. The conjugation allows for receptor-mediated transport across the blood-brain barrier (BBB) via low-density lipoprotein receptor-related protein 1 (LRP1), which is upregulated in many CNS tumors, including high-grade glioma and brain metastases. Once inside the cell, intracellular esterases release paclitaxel, which stabilizes microtubule formation by binding to β-tubulin, thereby halting mitosis and inducing apoptosis. This design enables paclitaxel delivery to the CNS, overcoming P-glycoprotein and multidrug resistance protein efflux mechanisms that limit standard paclitaxel efficacy in brain tumors. Clinical trials have shown activity in breast cancer patients with leptomeningeal carcinomatosis, recurrent brain metastases, glioblastoma, and other CNS malignancies[1][2][4][7][8].
- Brand names
- Paclitaxel trevatide
- Other names
- Paclitaxel trevatideANG1005ANG-1005ANG 1005GRN1005GRN-1005GRN 1005NG1005NG-1005NG 1005
02
Targets
TUBB (Tubulin (alpha and beta subunits))LRP1 (Prolow-density lipoprotein receptor-related protein 1)
Beyond the preview
Go deeper on paclitaxel trevatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel trevatide.